Prosecution Insights
Last updated: October 02, 2026
Application No. 18/682,681

PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4

Non-Final OA §102§112
Filed
Feb 09, 2024
Priority
Aug 10, 2021 — provisional 63/231,549 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Texas Heart Institute
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
879 granted / 1237 resolved
+11.1% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
97 currently pending
Career history
1309
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.2%
-22.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election without traverse of Group I, and species of PNG media_image1.png 36 528 media_image1.png Greyscale , in the reply filed on May 27, 2026 is acknowledged. 3. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be allowable. Therefore, the search and examination was extended. Prior art was found that anticipates the Markush claims with respect to a nonelected species. Thus, the Markush claims were rejected and nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and the nonelected species shown below. 4. Claims 3 and 12-16 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter. Election was made without traverse in the reply filed on May 27, 2026. Information Disclosure Statement 5. The information disclosure statements dated September 2, 2025 and February 9, 2024 were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 1449 are enclosed herewith. Claim Objections 6. Claim 24 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 7. Claims 1, 2, 4-11, 22 and 23 rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117. The Markush grouping of claims 1, 2, 4-11, 22 and 23 is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: the structure of the compounds does not share a common core. The core structure is defined in terms of variables X, Y, L1, L2 and variables R1-R3. This leads to various cores with the only common structural element shared by the cores being a carbonyl group. To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 8. Claim(s) 1, 2 and 5-9 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 209544-72-9 ( PNG media_image2.png 242 592 media_image2.png Greyscale ). The reference has a date of August 6, 1998 which antedate the present claims having an effective filing date of Jun 9, 2022 and priority claim to provisional application dated August 10, 2021. The compound corresponds to the present claims in the following manner: X=Y=CH2; L1=(CH2)n=1; L2=(CH2)m=0; R=R2=phenyl; R3=aryl. The compound also anticipates claim 5 in that the property is inseparable from the structure. Thus, the compound that meets the structural requirements also necessarily meets the limitation of claim 5. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Feb 09, 2024
Application Filed
Aug 12, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746246
COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
5y 0m to grant Granted Sep 29, 2026
Patent 12735424
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
2y 5m to grant Granted Sep 15, 2026
Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.3%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month